Novel Alternative Approach to Inhibiting Insulin Growth Factor may provide new Treatment for Breast Cancer and Other Cancers
Complete the form below to unlock access to ALL audio articles.
Cell Therapeutics, Inc. (CTI) and Systems Medicine, LLC (SM) has announced that preclinical data presented at the 19th annual AACR-NCI-EORTC Symposium show an antibody to IGF-II may solve the problems of low blood sugar associated with drug candidates working through insulin receptor-linked pathways.
The data presented is part of CTI's ongoing Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to develop products targeting the IGF pathway.
"While insulin-related growth factors play an important role in normal glucose metabolism and cell growth, the IGF pathway is increasingly being recognized as a critical contributor to growth of certain types of cancers," said Jack W. Singer, M.D., Chief Medical Officer of CTI.
"Many of the current approaches target blocking the IGF receptor or inhibition of post receptor kinases in an attempt to slow or kill tumor cell growth and are often associated with inhibition of insulin's important metabolic functions including maintaining normal blood glucose levels. By developing an antibody that binds to and neutralizes a specific form of insulin growth factor (IGF- II) the anti-tumor benefit may be retained without blocking the insulin receptor or associated post receptor signaling pathways, potentially allowing normal blood glucose and metabolic control," Singer added.
